After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
A five-year, $7 million program is led and supported by a coalition of local health institutions, including Eli Lilly and Co., Fairbanks School of Public Health and Eskenazi Health. It is based on a model that Lilly has used in other countries.